Directory
Headshot of Henry Mann

Henry Mann, PharmD, FCCP, FCCM, FASHP

Professor

Pharmacy Practice and Science
Research Areas: Division of Pharmacy Practice and Science

217 Parks Hall

mann.414@osu.edu
(614) 292-5711

Biography

Henry J. Mann is professor at The Ohio State University College of Pharmacy. Previously, he served as dean of The Ohio State University (2013-2023) and dean at the University of Toronto (2009-2013) where he directed implementation of the first English-language entry-to-practice PharmD program in Canada. Dr. Mann rose through the faculty ranks at the University of Minnesota where he also served as Associate Department Head for Pharmacy Practice, Associate Dean for Professional and External Relations and Associate Dean for Clinical Affairs. Dr. Mann was the founding director of the interdisciplinary Center for Excellence in Critical Care at Minnesota and of the national research network Partnership for Excellence in Critical Care. 

Dr. Mann has presented and published widely on the application of pharmacology and pharmacotherapy principles to critically ill patients. His contributions to research and practice have been recognized by election as a Fellow of the American College of Critical Care Medicine, the American College of Clinical Pharmacy, and the American Society of Health-Systems Pharmacists. He received the Research Award of the ASHP Research and Education Foundation and the Technology Enhanced Learning Award from the University of Minnesota. He also received the University of Minnesota Pharmacy Alumni Society Faculty Recognition Award and the Weaver Medal for Outstanding Contributions to the College. The University of Kentucky selected him to receive the Paul F. Parker Award which is given to recognize a resident of their program who has made outstanding contributions to pharmacy practice.

Publications

  • Kumar A, Mann HJ, Remmel RP, Beilman GJ, Kaila N. Pharmacokinetic study in pigs and in vitro metabolic characterization in pig- and human-liver microsomes reveal marked differences in disposition and metabolism of tiletamine and zolazepam (Telazol). Xenobiotica. 2014 Apr;44(4):379-90.
  • Kumar A, Mann HJ, Keshtgarpour M, Flynn MA, Deng H, Far AR, Parr TR, Moriarty SR. In vitro characterization of oritavancin clearance from human blood by low-flux, high-flux, and continuous renal replacement therapy dialyzers. Int J Artif Organs. 2011 Nov;34(11):1067-74.
  • Kumar A, Mann HJ, Keshtgarpour M, Flynn MA, Deng H, Far AR, Parr TR, Moriarty SR. In vitro characterization of oritavancin clearance from human blood by low-flux, high-flux, and continuous renal replacement therapy dialyzers. Int J Artif Organs. 2011 Nov;34(11):1067-74.
  • Kumar A, Mann HJ, Keshtgarpour M, Flynn MA, Deng H, Far AR, Parr TR, Moriarty SR. In vitro characterization of oritavancin clearance from human blood by low-flux, high-flux, and continuous renal replacement therapy dialyzers. Int J Artif Organs. 2011 Nov;34(11):1067-74.
  • Kumar A, Mann HJ, Keshtgarpour M, Flynn MA, Deng H, Far AR, Parr TR, Moriarty SR. In vitro characterization of oritavancin clearance from human blood by low-flux, high-flux, and continuous renal replacement therapy dialyzers. Int J Artif Organs. 2011 Nov;34(11):1067-74.
  • Cobb JP, Ognibene FP, Ingbar DH, Mann HJ, Hoyt DB, Angus DC, Thomas AV, Danner RL, Suffredini AF. Forging a critical alliance: Addressing the research needs of the United States critical illness and injury community. Crit Care Med. 2009 Dec;37(12):3158-60.
  • Mann HJ, Short MA, Schlichting DE. Protein C in critical illness. Am J Health Syst Pharm. 2009 Jun 15;66(12):1089-96.
  • Robertson TE, Mann HJ, Hyzy R, Rogers A, Douglas I, Waxman AB, Weinert C, Alapat P, Guntupalli KK, Buchman TG, Partnership for Excellence in Critical Care. Multicenter implementation of a consensus-developed, evidence-based, spontaneous breathing trial protocol. Crit Care Med. 2008 Oct;36(10):2753-62.
  • Erstad BL, Mann HJ, Weber RJ. Developing a Business Plan for Critical Care Pharmacy Services. Hosp Pharm. 2016 Nov;51(10):856-862.